Metastatic NSCLC with G719X/S781I EGFR-mutations with acquired BRAF V600E mutation - response to Osimertinib, Dabrafenib and Trametinib

被引：0
|
作者：
Urbanska, E. M. [1 ]
Sorensen, J. B. [1 ]
Melchior, L. C. [1 ]
Santoni-Rugiu, E. [1 ]
机构：
[1] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
acquired BRAF V600E; uncommon EGFR mutations; Osimertinib; Dabrafenib; Trametinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-06
引用
收藏
页码：S642 / S642
页数：1
相关论文
共 43 条
  • [41] Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma
    Robert, C.
    Karaszewska, B.
    Schachter, J.
    Rutkowski, P.
    Mackiewicz, A.
    Stroyakovskiy, D.
    Lichinitser, M.
    Dummer, R.
    Grange, F.
    Mortier, L.
    Chiarion-Sileni, V.
    Drucis, K.
    Krajsova, I.
    Hauschild, A.
    Mookerjee, B.
    Legos, J.
    Schadendorf, D.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S663 - S664
  • [42] Prolonged response to first-generation tyrosine kinase inhibitor in a metastatic non-small cell lung cancer harbouring complex G719X and S768I mutations: A case report from Vietnam and literature review
    Do, Kien Hung
    Le, Duc Thanh
    Nguyen, Tai Van
    Do, Tu Anh
    Nguyen, Chu Van
    RESPIROLOGY CASE REPORTS, 2023, 11 (05):
  • [43] How to select between osimertinib or afatinib in P-loop and αC-helix compressing (G719X, S768I) or classical-like (L861Q) EGFR mutations: what preclinical models and clinical data have taught us in the early 2020s
    Berg, Julia M.
    Kobayashi, Toshiki A.
    Costa, Daniel B.
    TRANSLATIONAL CANCER RESEARCH, 2025, 14 (01) : 16 - 23
12345